Investor Relations Captor Therapeutics ®
Current
-
-
Publication date:
Publication time:
RB ESPI 46/2024 Adoption of a resolution by the Company's Management Board on the issue of shares within the framework of a target share capital increase -
Publication date:
Publication time:
RB ESPI 45/2024 Communication from the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on the registration in the depository for securities of the rights to series T ordinary bearer s
-
Publication date:
Publication time:
RB ESPI 44/2024 Admission and listing of rights to series T ordinary bearer shares.
-
Publication date:
Publication time:
RB ESPI 43/2024 Obtaining approval for a phase 1 clinical trial in patients with hepatocellular carcinoma
-
Publication date:
Publication time:
RB ESPI 42/2024 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 41/2024 Communication from the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on conditional registration of rights to series T ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 40/2024 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 39/2024 Summary of subscription of T shares
-
Publication date:
Publication time:
RB ESPI 38/2024 Allocation of ordinary bearer shares of series T of the Company
-
Publication date:
Publication time:
RB ESPI 37/2024 Completion of the book-building process for the offering of new series T bearer shares and determination of the issue price for series T shares
-
Publication date:
Publication time:
RB ESPI 36/2024 Adoption of a resolution by the Company's Management Board on the issue of shares as part of an authorised share capital increase
-
Publication date:
Publication time:
RB ESPI 35/2024 Commencement of the bookbuilding process for the offering of new series T bearer shares and conclusion of the share offering placement agreement
-
Publication date:
Publication time:
RB ESPI 34/2024 Change of the publication date of the quarterly report for Q3 2024
-
Publication date:
Publication time:
RB ESPI 33/2024 Selection of a clinical candidate in the CT-03 project
-
Publication date:
Publication time:
RB ESPI 32/2024 Publication of the revised half-yearly report for the period from 01.01.2024 to 30.06.2024
-
Publication date:
Publication time:
RB ESPI 31/2024 Submission of application for approval of a phase 1 clinical trial in patients with hepatocellular carcinoma
-
Publication date:
Publication time:
RB ESPI 30/2024 Completion of subscription for series S shares issued in connection with the Company's employee incentive scheme
-
Publication date:
Publication time:
RB ESPI 29/2024 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 28/2024 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 27/2024 Communication from the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on the registration of series R ordinary bearer shares in the depository for securities
-
Publication date:
Publication time:
RB ESPI 26/2024 Admission and introduction to exchange trading of series R ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 25/2024 Announcement from the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on the conditional registration of series R ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 24/2024 Notification of increase in shareholding
-
Publication date:
Publication time:
RB ESPI 23/2024 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 22/2024 Registration of amendments to the Articles of Association of the Company
-
Publication date:
Publication time:
RB ESPI 21/2024 List of shareholders holding at least 5% of votes at the Company's Annual General Meeting on 27 June 2024
-
Publication date:
Publication time:
RB ESPI 20/2024 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 19/2024 Contents of the resolutions passed by the Annual General Meeting of 27 June 2024
-
Publication date:
Publication time:
RB ESPI 18/2024 Registration of amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 17/2024 Obtaining positive results from the in vivo study in the CT-02 project
-
Publication date:
Publication time:
RB ESPI 16/2024 Conclusion of the contract for the phasing of the CT-01 project
-
Publication date:
Publication time:
ESPI RB 15/2024 Notice of convocation of the Annual General Shareholders Meeting and documents related to the Annual General Meeting
-
Publication date:
Publication time:
RB ESPI 14/2024 Adoption of a resolution by the Company's Management Board on the issue of shares within the framework of a target share capital increase
-
Publication date:
Publication time:
RB ESPI 13/2024 Completion of subscription for series R shares issued in connection with the Company's employee incentive scheme
-
Publication date:
Publication time:
RB ESPI 12/2024 Notification from the National Centre for Research and Development that the CT-01 project has been selected for funding for the second phase of this project
-
Publication date:
Publication time:
RB ESPI 11/2024 Conclusion of the contract for the phasing of the CT-03 project
-
Publication date:
Publication time:
RB ESPI 10/2024 Information on transactions in the Company's shares obtained pursuant to Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 9/2024 List of shareholders holding at least 5% of votes at the Company's Extraordinary General Meeting on 20 March 2024.
-
Publication date:
Publication time:
RB ESPI 8/2004 Content of resolutions adopted by the Extraordinary General Meeting of 20 March 2024.
-
Publication date:
Publication time:
RB ESPI 7/2024 Notification from the National Centre for Research and Development that the CT-01 project has not been selected for funding for the second phase of this project
-
Publication date:
Publication time:
RB ESPI 6/2024 Notice of convocation of the Extraordinary General Shareholders Meeting and documents related to the Extraordinary General Meeting
-
Publication date:
Publication time:
RB ESPI 5/2024 Resignation of the Member of the Management Board - Chief Financial Officer
-
Publication date:
Publication time:
RB ESPI 4/2024 Adoption of a resolution by the Company's Management Board on the issue of shares within the framework of a target share capital increase
-
Publication date:
Publication time:
RB ESPI 3/2024 Dates of publication of periodic reports in 2024
-
Publication date:
Publication time:
RB ESPI 2/2024 List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on 4 January 2024
-
Publication date:
Publication time:
RB ESPI 1/2024 Contents of resolutions adopted by the Extraordinary General Meeting on January 4, 2024, dismissal and appointment of a member of the Company's Supervisory Board
-
-
-
Publication date:
Publication time:
RB ESPI 61/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB_ESPI 60/2023 Candidate for member of the Supervisory Board of the Company
-
Publication date:
Publication time:
RB_ESPI 59/2023 Notice of convocation of the Extraordinary General Shareholders Meeting and documents related to the Extraordinary General Meeting
-
Publication date:
Publication time:
RB ESPI 58/2023 Shareholder's request to convene a General Meeting of the Company and to include certain items on the agenda
-
Publication date:
Publication time:
RB ESPI 57/2023 Information on research and development progress in the CT-03 project
-
Publication date:
Publication time:
RB ESPI 56/2023 Information on research and development progress in the CT-02 project
-
Publication date:
Publication time:
RB ESPI 55/2023 Information on the status of the Company's projects and submission of phasing applications
-
Publication date:
Publication time:
RB ESPI 54/2023 Announcement of the National Depository for Securities S.A. on the registration in the depository of securities of ordinary bearer shares of series N, O and P
-
Publication date:
Publication time:
RB ESPI 53/2023 Summary of P share subscription - supplement to current report no. 45/2023 of 11 October 2023
-
Publication date:
Publication time:
RB ESPI 51/2023 Communication from the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on the conditional registration of ordinary bearer shares of series P
-
Publication date:
Publication time:
RB ESPI 50/2023 Notification under Article 69 of the Act on Public Offering - change in a significant block of shares
-
Publication date:
Publication time:
RB ESPI 49/2023 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 48/2023 Communication from the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on the conditional registration of ordinary bearer shares of series N and O
-
Publication date:
Publication time:
RB ESPI 47/2023 Communication from the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on the conditional registration of the rights to series P ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 46/2023 Conclusion of service contracts for Phase I clinical trials for the CT-01 project with ICON Clinical Research Limited
-
Publication date:
Publication time:
RB ESPI 45/2023 Summary of P share subscription
-
Publication date:
Publication time:
RB ESPI 44/2023 Allocation of series P ordinary bearer shares of the Company
-
Publication date:
Publication time:
RB ESPI 43/2023 Completion of the book-building process for the offering of new series P bearer shares and determination of the issue price for series P shares
-
Publication date:
Publication time:
RB ESPI 42/2023 Adoption of a resolution by the Management Board on the issue of shares as part of an authorised share capital increase.
-
Publication date:
Publication time:
RB ESPI 41/2023 Commencement of book-building process for the offering of new P series bearer shares and conclusion of the share offering placement agreement.
-
Publication date:
Publication time:
RB ESPI 40/2023 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 39/2023 Registration of an amendment to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 38/2023 Conclusion of an annex extending the cooperation with Wedbush Securities Inc.
-
Publication date:
Publication time:
RB ESPI 37/2023 Text of resolutions adopted by the Extraordinary General Meeting on 5 September 2023
-
Publication date:
Publication time:
RB ESPI 36/2023 Completion of subscription for series O shares issued in connection with the Company's employee incentive scheme
-
Publication date:
Publication time:
RB ESPI 35/2023 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 33/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 32/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 31/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 30/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 29/2023 Adoption of a resolution by the Company's Management Board on the issue of shares within the framework of a target share capital increase
-
Publication date:
Publication time:
RB ESPI 28/2023 Conclusion of an agreement with the Medical Research Agency for the implementation and funding of a project to develop an oral molecular adhesive drug candidate for the treatment of colorectal cancer
-
Publication date:
Publication time:
RB ESPI 27/2023 Update on terminated grant agreement with NCBiR for CT-02 project
-
Publication date:
Publication time:
RB ESPI 26/2023 List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on 26 June 2023
-
Publication date:
Publication time:
RB ESPI 25/2023 Text of resolutions adopted by the Ordinary General Meeting on 26 June 2023
-
Publication date:
Publication time:
RB ESPI 24/2023 Update on the termination of the grant agreement with the NCBiR concerning project CT-02
-
Publication date:
Publication time:
RB ESPI 23/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 22/2023 Recommendation of the Captor Therapeutics project for funding by the Medical Research Agency
-
Publication date:
Publication time:
RB ESPI 21/2023 Information on receipt of a statement on termination of the grant agreement concluded with NCBiR concerning project CT-02
-
Publication date:
Publication time:
RB ESPI 20/2023 Notice convening the Ordinary Shareholders Meeting and documents relating to the Ordinary Shareholders Meeting
-
Publication date:
Publication time:
RB ESPI 19/2023 Registration of an amendment to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 18/2023 Completion of subscription of N-series shares issued in connection with the Company's employee incentive programme
-
Publication date:
Publication time:
RB ESPI 17/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 16/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 15/2023 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 14/2023 List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on 3 April 2023
-
Publication date:
Publication time:
RB ESPI 13/2023 Text of resolutions adopted by the Extraordinary General Meeting on 3 April 2023
-
Publication date:
Publication time:
RB ESPI 12/2023 Information on progress in research and development related to the CT-01, CT-02 and CT-05 projects and information on the molecular targets of these projects
-
Publication date:
Publication time:
RB ESPI 11/2023 Change of the publication date of the separate annual report and consolidated annual report for the financial year 2022
-
Publication date:
Publication time:
RB ESPI 10/2023 Announcement of the National Securities Depository S.A. on the registration of series M ordinary bearer shares in the securities depository
-
Publication date:
Publication time:
RB ESPI 9/2023 Admission and introduction to exchange trading of series M ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 7/2023 Captor Therapeutics S.A.'s strategic plans for 2023-2025.
-
Publication date:
Publication time:
RB ESPI 6/2023 Completion of subscription for series M shares issued in connection with the implementation of the Company's employee incentive programme
-
Publication date:
Publication time:
RB ESPI 5/2023 Announcement of the Central Securities Depository of Poland on the conditional registration of series M ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 4/2023 Information on receipt of NCBR's letter of completion for project CT-04
-
Publication date:
Publication time:
RB ESPI 3/2023 Adoption of a resolution by the Company's Management Board on the issue of shares within the framework of a target share capital increase
-
Publication date:
Publication time:
RB ESPI 2/2023 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 1/2023 Dates of publication of periodic reports in 2023
-
-
-
Publication date:
Publication time:
RB ESPI 49/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 48/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 47/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 45/2022 Information on expiration of pledge in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 44/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 43/2022 Admission and introduction to exchange trading of series L ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 42/2022 Announcement of the Central Securities Depository of Poland on the conditional registration of series L ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 41/2022 Final settlement of audit results with NCBiR
-
Publication date:
Publication time:
RB ESPI 40/2022 Conclusion of a collaboration agreement with Ono Pharmaceutical Co., Ltd. and disclosure of delayed confidential information
-
Publication date:
Publication time:
RB ESPI 39/2022 Completion of subscription of series L shares issued in connection with the implementation of the Company's employee incentive scheme
-
Publication date:
Publication time:
RB ESPI 38/2022 Information on the status of the CT-04 project
-
Publication date:
Publication time:
RB ESPI 37/2022 Adoption of a resolution by the Company's Management Board on the issue of shares within the framework of a target share capital increase
-
Publication date:
Publication time:
RB ESPI 36/2022 Registration of the amendment to the Company's Articles of Association
-
Publication date:
Publication time:
RB EBI 35/2022 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 34/2022 Change of the publication date of the extended consolidated semi-annual report for the first half of 2022
-
Publication date:
Publication time:
RB ESPI 33/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB EBI 32/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 31/2022 Progress in research and development related to CT-01 project
-
Publication date:
Publication time:
RB ESPI 30/2022 List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on 14 July 2022
-
Publication date:
Publication time:
RB ESPI 29/2022 Contents of the resolutions passed by the Annual General Meeting of Captor Therapeutics S.A. after the resumption of the meeting on 14 July 2022.
-
Publication date:
Publication time:
RB ESPI 28/2022 List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on 30 June 2022
-
Publication date:
Publication time:
RB ESPI 27/2022 Appointment of the Company's Supervisory Board, Management Board, Audit Committee and Remuneration Committee for the next term
-
Publication date:
Publication time:
RB ESPI 26/2022 Announcement of the National Securities Depository S.A. on the registration of series K ordinary bearer shares in the securities depository
-
Publication date:
Publication time:
RB ESPI 25/2022 Announcement of a break in the Ordinary General Meeting of Captor Therapeutics S.A. on 30 June 2022 and the content of the resolutions adopted until the break
-
Publication date:
Publication time:
RB EBI 24/2022 Admission and introduction to exchange trading of series K ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 23/2022 Announcement of the Central Securities Depository of Poland on the conditional registration of series K ordinary bearer shares
-
Publication date:
Publication time:
RB ESPI 22/2022 Completion of subscription of series K shares issued in connection with the implementation of the Company's employee incentive scheme
-
Publication date:
Publication time:
RB ESPI 21/2022 Submitting Candidates for Members of the Supervisory Board of the Company
-
Publication date:
Publication time:
RB ESPI 20/2022 Notice of convocation of the Ordinary General Shareholders Meeting and draft resolutions of the Ordinary General Shareholders Meeting
-
Publication date:
Publication time:
RB ESPI 19/2022 Potential delays to the Company's project
-
Publication date:
Publication time:
RB ESPI 18/2022 Change of the publication date of the extended consolidated quarterly report for Q1 2022
-
Publication date:
Publication time:
RB ESPI 17/2022 Registration of share capital increase and amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 16/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 14/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 13/2022 Adoption of a resolution by the Company's Management Board concerning the issuance of shares as part of an authorized share capital increase
-
Publication date:
Publication time:
RB ESPI 12/2022 Progress in research and development related to CT-01 project
-
Publication date:
Publication time:
RB ESPI 11/2022 Disclosure of molecular targets in CT-01 project
-
Publication date:
Publication time:
RB ESPI 10/2022 Information on receipt by the Company of the results of the Audit
-
Publication date:
Publication time:
RB ESPI 9/2022 Progress in research and development related to CT-03 project
-
Publication date:
Publication time:
RB ESPI 8/2022 List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on 21 February 2022
-
Publication date:
Publication time:
RB ESPI 15/2022 Information on transaction in Company shares under Article 19 MAR
-
Publication date:
Publication time:
RB ESPI 7/2022 Text of resolutions adopted by the Extraordinary General Meeting on 21 February 2021
-
Publication date:
Publication time:
RB ESPI 6/2022 Dates of publication of periodic reports in 2022
-
Publication date:
Publication time:
RB ESPI 5/2022 Filing by the Company of notification to NCBiR regarding potential irregularities in settlement of eligible costs in EU projects
-
Publication date:
Publication time:
RB ESPI 4/2022 Announcement of convening Extraordinary General Meeting together with draft resolutions
-
Publication date:
Publication time:
RB ESPI 3/2022 Progress in research and development related to CT-01 project
-
Publication date:
Publication time:
RB ESPI 2/2022 Appointment of a member of the Company's Supervisory Board
-
Publication date:
Publication time:
RB ESPI 1/2022 Information on transaction in Company shares under Article 19 MAR
-
-
-
Publication date:
Publication time:
RB ESPI 31/2021 Notification of increase in shareholding
-
Publication date:
Publication time:
RB ESPI 30/2021 Notification of increase in shareholding
-
Publication date:
Publication time:
RB ESPI 29/2021 Registration of amendments to the Company's Articles of Association
-
Publication date:
Publication time:
RB ESPI 28/2021 The Company purchased specialized laboratory equipment
-
Publication date:
Publication time:
RB ESPI 27/2021 Progress in research and development related to CT-3 project and disclosure of molecular target in CT-3 project
-
Publication date:
Publication time:
RB ESPI 26/2021 Conclusion of a service agreement concerning, among others, investor relations
-
Publication date:
Publication time:
RB ESPI 25/2021 Zakończenie subskrypcji akcji serii G oraz sprzedaży części akcji serii B w ofercie publicznej – uzupełnienie raportu bieżącego nr 4/2021 z 15 kwietnia 2021 r.
-
Publication date:
Publication time:
RB ESPI 24/2021 Appointment of an audit firm (extension of an audit agreement)
-
Publication date:
Publication time:
RB ESPI 23/2021 Information on a transaction in shares of the Company obtained pursuant to Article 19 of MAR
-
Publication date:
Publication time:
RB ESPI 22/2021 Notice of reduction of shareholding interest in Company
-
Publication date:
Publication time:
RB ESPI 21/2021 List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on 29 June 2021
-
Publication date:
Publication time:
RB ESPI 20/2021 Text of resolutions adopted by the Ordinary General Meeting on 29 June 2021
-
Publication date:
Publication time:
RB ESPI 19/2021 Appointment of a member of the Company's Management Board and the Chief Financial Officer
-
Publication date:
Publication time:
RB ESPI 18/2021 Resignation of a member of the Company's Management Board
-
Publication date:
Publication time:
RB ESPI 17/2021 Announcement of KDPW on registration of G series shares in securities depository
-
Publication date:
Publication time:
RB ESPI 16/2021 Designation of the last day of listing of the rights to G series shares and introduction of G series shares to exchange trading
-
Publication date:
Publication time:
RB ESPI 15/2021 A shareholder’s request to include certain matters on the agenda of the Ordinary General Meeting called for 29 June 2021
-
Publication date:
Publication time:
RB ESPI 14/2021 Notice of convocation of the Ordinary General Shareholders Meeting and draft resolutions of the Ordinary General Shareholders Meeting
-
Publication date:
Publication time:
RB ESPI 33/2021 Resignation of a member of the Company's Supervisory Board
-
Publication date:
Publication time:
RB ESPI 32/2021 Adoption of a resolution by the Company's Management Board concerning the issuance of shares as part of an authorized share capital increase
-
Publication date:
Publication time:
RB ESPI 13/2021 Notice of reduction of shareholding interest in Company
-
Publication date:
Publication time:
RB ESPI 12/2021 Notice of reduction of shareholding interest in Company
-
Publication date:
Publication time:
RB ESPI 11/2021 Notice of reduction of shareholding interest in Company
-
Publication date:
Publication time:
RB ESPI 10/2021 Notice of reduction of shareholding interest in Company
-
Publication date:
Publication time:
RB ESPI 9/2021 Notice of reduction of shareholding interest in the Company
-
Publication date:
Publication time:
RB ESPI 8/2021 Registration of the increase of the share capital through the issuance of G series shares
-
Publication date:
Publication time:
RB ESPI 7/2021 Dates of publication of interim reports
-
Publication date:
Publication time:
RB ESPI 6/2021 Introduction of shares and rights to shares to trading on a regulated market
-
Publication date:
Publication time:
RB ESPI 5/2020 KDPW announcements on registration of shares and rights to shares in the securities depository
-
Publication date:
Publication time:
RB ESPI 4/2021 Closing of the subscription of G series shares and sale of a part of B series shares in a public offering
-
Publication date:
Publication time:
RB ESPI 3/2021 Admission of shares and rights to shares to trading
-
Publication date:
Publication time:
RB ESPI 2/2021 Registration of outstanding shares and rights to shares in KDPW
-
Publication date:
Publication time:
RB ESPI 1/2021 Granting of access to the Electronic Reporting System (“ERS”)
-